Arbutus Biopharma Corp: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 5, 2019 and accepted by EDGAR at Aug 5, 2019, 12:29 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $653.0k | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $1.3m | us-gaap:Revenues |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $12.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $27.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$20.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$39.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $2.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $14.0k | us-gaap:InterestExpense |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$23.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$46.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.46 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$0.92 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | −$0.46 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | −$0.92 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 56,805,583 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-01-01 to 2019-06-30 | 56,275,795 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2019-04-01 to 2019-06-30 | −$17.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$34.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2019-04-01 to 2019-06-30 | $240.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $271.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $78.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $99.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $192.6m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $8.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $28.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $164.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001447028-19-000025. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.